ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of AUD 53.37 billion. The enterprise value is 53.87 billion.

Market Cap	53.37B
Enterprise Value	53.87B

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	Feb 12, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.93M

Valuation Ratios

The trailing PE ratio is 26.45.

PE Ratio	26.45
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	16.44
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.51, with an EV/FCF ratio of 23.95.

EV / Earnings	26.70
EV / Sales	6.97
EV / EBITDA	19.51
EV / EBIT	21.96
EV / FCF	23.95

Financial Position

The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.16.

Current Ratio	3.33
Quick Ratio	1.74
Debt / Equity	0.16
Debt / EBITDA	0.48
Debt / FCF	0.60
Interest Coverage	65.73

Financial Efficiency

Return on equity (ROE) is 25.65% and return on invested capital (ROIC) is 16.30%.

Return on Equity (ROE)	25.65%
Return on Assets (ROA)	13.89%
Return on Invested Capital (ROIC)	16.30%
Return on Capital Employed (ROCE)	24.81%
Revenue Per Employee	797,713
Profits Per Employee	202,183
Employee Count	9,980
Asset Turnover	0.70
Inventory Turnover	1.91

Taxes

In the past 12 months, ResMed has paid 335.18 million in taxes.

Income Tax	335.18M
Effective Tax Rate	18.95%

Stock Price Statistics

The stock price has increased by +32.48% in the last 52 weeks. The beta is 0.70, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.70
52-Week Price Change	+32.48%
50-Day Moving Average	37.93
200-Day Moving Average	34.96
Relative Strength Index (RSI)	32.20
Average Volume (20 Days)	1,202,402

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.50

Income Statement

In the last 12 months, ResMed had revenue of AUD 7.96 billion and earned 2.02 billion in profits. Earnings per share was 13.69.

Revenue	7.96B
Gross Profit	4.70B
Operating Income	2.52B
Pretax Income	2.48B
Net Income	2.02B
EBITDA	2.77B
EBIT	2.52B
Earnings Per Share (EPS)	13.69

Full Income Statement

Balance Sheet

The company has 843.41 million in cash and 1.36 billion in debt, giving a net cash position of -513.52 million.

Cash & Cash Equivalents	843.41M
Total Debt	1.36B
Net Cash	-513.52M
Net Cash Per Share	n/a
Equity (Book Value)	8.49B
Book Value Per Share	57.80
Working Capital	3.21B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.39 billion and capital expenditures -136.63 million, giving a free cash flow of 2.25 billion.

Operating Cash Flow	2.39B
Capital Expenditures	-136.63M
Free Cash Flow	2.25B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.02%, with operating and profit margins of 31.67% and 25.35%.

Gross Margin	59.02%
Operating Margin	31.67%
Pretax Margin	31.16%
Profit Margin	25.35%
EBITDA Margin	34.75%
EBIT Margin	31.67%
FCF Margin	28.25%

Dividends & Yields

This stock pays an annual dividend of 0.47, which amounts to a dividend yield of 1.30%.

Dividend Per Share	0.47
Dividend Yield	1.30%
Dividend Growth (YoY)	-64.81%
Years of Dividend Growth	n/a
Payout Ratio	23.76%
Buyback Yield	0.02%
Shareholder Yield	1.32%
Earnings Yield	3.78%
FCF Yield	4.21%

Dividend Details

Stock Splits

The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 12, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.76 and a Piotroski F-Score of 5.

Altman Z-Score	12.76
Piotroski F-Score	5